Viking Therapeutics, Inc.
VKTX
$33.80
-$0.64-1.86%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -128.02M | -158.33M | -157.66M | -90.79M | -65.56M |
| Total Depreciation and Amortization | 157.00K | 85.00K | 94.00K | 114.00K | 112.00K |
| Total Amortization of Deferred Charges | -- | -- | 0.00 | 8.00K | 24.00K |
| Total Other Non-Cash Items | 10.33M | 9.05M | 6.80M | 5.31M | 11.16M |
| Change in Net Operating Assets | -7.64M | 35.22M | 65.48M | -8.64M | 7.20M |
| Cash from Operations | -125.17M | -113.98M | -85.29M | -94.00M | -47.06M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 109.43M | 54.19M | 75.61M | 160.03M | 42.51M |
| Cash from Investing | 109.43M | 54.19M | 75.61M | 160.03M | 42.51M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 23.59M | 12.08M | 75.10M | 480.00K | 507.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 23.59M | 12.08M | 75.10M | 480.00K | 507.00K |
| Foreign Exchange rate Adjustments | 0.00 | 16.00K | 9.00K | -6.00K | -12.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 7.85M | -47.69M | 65.43M | 66.50M | -4.06M |